Published: 12/23/2020 23:29 GMT (UROV) - Urovant Sciences Announces U.S. FDA Approval of Gemtesa® (vibegron) 75 Mg Tablets for the Treatment of Patients With Overactive Bladder (oab).
Urovant Sciences Ltd - U.S. Commercial Launch Planned in Late-q1 2021 for Gemtesa.
